Further enhancing its position as the foremost provider of strategic research solutions in healthcare, RG+A has appointed Ellen Gordon as Senior Vice President and Head of Research.
We will discuss “Line of Therapy” treatment simulation methodology, an innovation that allows researchers to forecast the next five years of market development in these disease classes.
RG+A has recently implemented some key staffing changes to support the company’s ongoing growth in its biopharma forecasting and device/diagnostics lines of business.
Join us as we present at PRMG Connect in Orlando, FL!
In this workshop, you will learn how to design and build models quickly and efficiently while managing the statistical error inherent in any forward-looking exercise. The workshop itself will combine didactic learning with group exercises to provide a sense of critical success factors in building models under uncertainty and offer a couple of specific tricks you can use in organizing the process.
Complex Diseases: Challenges in Forecasting Physician Treatment Decisions under Multiple Market Scenarios
In this session, we will focus on some of the common assumptions marketers and researchers make that can lead to models, strategies and product positions that are simply wrong, and how to avoid the assumptions that lead to these errors. The presenters will build on RG+A’s extensive history in market simulation and modeling, including errors we have seen, to provide some simple benchmarks for building better forecasts and support tools.
According to members of RG+A’s Health Payer Council® (HPC®), an online community of managed care pharmacy and medical directors, biosimilar products are likely to continue to face the same scrutiny and pricing pressure from payers as their innovator counterparts, as well as competition from other biosimilar products.
RG+A Continues its Long-Standing Commitment to the Trenton Area Soup Kitchen and Says Farewell to an Exemplary Leader
Company staff volunteer time, supplies and money to “feed the need” continuing a tradition of honoring Marty Green, the father of RG+A’s President and CEO.
In this session, Ms. Park will discuss some of the commercial imperatives that led Quest to make improvement and tracking of customer experience and Mr. Martin will describe some of the methodological and practical challenges that RG+A faced when creating a set of marketing research tools and studies to support Quest’s efforts. In the process, the two will address issues such as identifying the proper study design and core measures, challenges inherent in tying customer experience to financial metrics in a complex, multi-stakeholder environment, and how companies looking to upgrade their customer experience activities might proceed to do so in a systematic way.
Small sample research, once the way to “do it on the cheap,” has now become a pivotal tool for all kinds of research exercises. In this workshop, you’ll learn that small sample size doesn’t have to mean sacrificing the quality of the research. Using recent studies as a backdrop, we’ll show how some new methods – and new ways of looking at old ones – can help studies with small sample sizes produce projectable and actionable insights.
RG+A’s new Dynamic Practice Simulation® Line of Therapy overcomes challenges in forecasting treatment decisions for current and emerging options within highly complex diseases.
Company staff volunteer time, supplies and money to local cause in honor of Marty Green, the father of RG+A President and CEO.
Company staff volunteer time, supplies and money to local cause in honor of Marty Green, the father of RG+A President and CEO. Trenton, NJ – – RG+A’s President/CEO, Roger Green along with staff, pictured above, celebrated ten years of giving back to the community by volunteering at the Trenton Area Soup Kitchen (TASK) to serve […]
RG+A Expands Leadership Team with Appointment of New Executive Vice President and Chief Operating Officer
RG+A positioned for next phase of growth with the selection of industry leader Kevin M. Kelly as the company’s Executive Vice President and Chief Operating Officer.
During their talk, Dr. Hamilton and Mr. Green discussed the impact of the Sovaldi launch and other upcoming blockbuster launches on how health plans monitor and plan for new launches. Dr. Hamilton anticipated a future where payers refuse guidelines from groups like AASLD. Mr. Green noted a change in the calculus for new medicines from cost:benefit or cost:efficiency ratios to a more basic question: “can we afford the out-of-pocket cost of reaping long-term benefits?” They concluded that plans will increase advance surveillance and post-launch control of medicines that threaten to increase cost of drug therapy dramatically.